Market Research Logo

Opium (Opioid) Addiction - Pipeline Review, H2 2016

Opium (Opioid) Addiction - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Opium (Opioid) Addiction - Pipeline Review, H2 2016’, provides an overview of the Opium (Opioid) Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction
    • The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects
    • The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Opium (Opioid) Addiction Overview
    Therapeutics Development
    Pipeline Products for Opium (Opioid) Addiction - Overview
    Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis
    Opium (Opioid) Addiction - Therapeutics under Development by Companies
    Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes
    Opium (Opioid) Addiction - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Opium (Opioid) Addiction - Products under Development by Companies
    Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes
    Opium (Opioid) Addiction - Companies Involved in Therapeutics Development
    Alkermes Plc
    Aoxing Pharmaceutical Company, Inc
    BioDelivery Sciences International, Inc.
    Camurus AB
    Foresee Pharmaceuticals, LLC
    Heron Therapeutics, Inc.
    Indivior Plc
    INSYS Therapeutics, Inc.
    Omeros Corporation
    Pfizer Inc.
    Relmada Therapeutics, Inc.
    Teva Pharmaceutical Industries Ltd.
    Titan Pharmaceuticals, Inc.
    Zynerba Pharmaceuticals, Inc.
    Opium (Opioid) Addiction - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    buprenorphine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    buprenorphine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    buprenorphine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    buprenorphine hydrochloride depot - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    buprenorphine hydrochloride ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    buprenorphine hydrochloride long acting - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    buprenorphine hydrochloride SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cannabidiol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cannabidiol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FP-004 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    naltrexone hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    naltrexone hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMS-405 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMS-527 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ORP-107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PF-5006739 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    samidorphan l-malate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TA-CD - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TEV-90109 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Opium Addiction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Opium (Opioid) Addiction - Dormant Projects
    Opium (Opioid) Addiction - Discontinued Products
    Opium (Opioid) Addiction - Product Development Milestones
    Featured News & Press Releases
    Aug 16, 2016: Indivior Announces Positive Top-line Phase 3 Pivotal Study Results for RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder
    Aug 02, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Juan on August 5, 6 and 7 for Qualified Healthcare Providers
    Jul 26, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Burlington on July 29 and 30 for Qualified Healthcare Providers
    Jul 19, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings on July 22, 23 and 24 for Qualified Healthcare Providers in US
    Jul 19, 2016: Buprenorphine implants may be effective relapse prevention tool for adults with opioid dependence
    Jul 12, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Tampa on July 15, 16 and 17 for Qualified Healthcare Providers
    Jun 29, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Antonio on July 8 and 9 for Qualified Healthcare Providers
    Jun 21, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in St. Louis on June 24 and 25 for Qualified Healthcare Providers
    Jun 20, 2016: Titan Pharmaceuticals Announces First Patients Treated With Probuphine For Opioid Dependence
    Jun 16, 2016: Probuphine (buprenorphine) Implant Phase 3 Data Presented at CPDD Annual Scientific Meeting
    Jun 15, 2016: Titan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine for Opioid Dependence
    Jun 14, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Francisco on June 17, 18 and 19 for Qualified Healthcare Providers
    Jun 13, 2016: Titan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine
    Jun 09, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Louisville on June 10, 11 and 12 for Qualified Healthcare Providers
    Jun 07, 2016: MonoSol Rx Wins Patent Infringement Suit Against Par Pharmaceutical and Watson Pharmaceuticals Related to Suboxone Sublingual Film
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Opium (Opioid) Addiction, H2 2016
    Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H2 2016
    Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2016
    Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International, Inc., H2 2016
    Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2016
    Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016
    Opium (Opioid) Addiction - Pipeline by Heron Therapeutics, Inc., H2 2016
    Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2016
    Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H2 2016
    Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H2 2016
    Opium (Opioid) Addiction - Pipeline by Pfizer Inc., H2 2016
    Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H2 2016
    Opium (Opioid) Addiction - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
    Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals, Inc., H2 2016
    Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Opium (Opioid) Addiction - Dormant Projects, H2 2016
    Opium (Opioid) Addiction - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Opium (Opioid) Addiction, H2 2016
    Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report